Cargando…

ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV

OBJECTIVE: We investigated whether apolipoprotein A-I (apoA-I) mimetic peptides 4F and 6F can be a novel therapeutic strategy to reduce blood and gut bioactive lipids, proinflammatory effects of endotoxin (LPS) and aberrant activation of cyclooxygenase 2 (COX-2) as instigators of increased risk for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daskou, M., Sharma, M., Mu, W., Heymans, R., Ritou, E., Rezek, V., Hamid, P., Kossyvakis, A., Sen Roy, S., Grijalva, V., Chattopadhyay, A., Papesh, J., Meriwether, D., Kitchen, S.G., Fogelman, A.M., Reddy, S.T., Kelesidis, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802211/ https://www.ncbi.nlm.nih.gov/pubmed/34509494 http://dx.doi.org/10.1016/j.metabol.2021.154888

Ejemplares similares

ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
por: Daskou, Maria, et al.
Publicado: (2022)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer
por: Chattopadhyay, Arnab, et al.
Publicado: (2018)

The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells
por: Theodoros, Kelesidis, et al.
Publicado: (2021)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration
por: Chen, Xun, et al.
Publicado: (2009)

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice
por: Marino, J S, et al.
Publicado: (2012)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023)

ApoA-1 in Diabetes: Damaged Goods
por: Ory, Daniel S., et al.
Publicado: (2010)

Crystallization of ApoA1 and ApoE4 nanolipoprotein particles and initial XFEL-based structural studies
por: Shelby, M.L., et al.
Publicado: (2020)

ApoA-I Mimetic Peptide Reduces Vascular and White Matter Damage After Stroke in Type-2 Diabetic Mice
por: Wang, Xiaohui, et al.
Publicado: (2019)

FAMP, a Novel ApoA‐I Mimetic Peptide, Suppresses Aortic Plaque Formation Through Promotion of Biological HDL Function in ApoE‐Deficient Mice
por: Uehara, Yoshinari, et al.
Publicado: (2013)

An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI
por: Song, Xuelei, et al.
Publicado: (2009)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

The unsolved mystery of apoA-I recycling in adipocyte
por: Wang, Shuai, et al.
Publicado: (2016)

D-4F, an ApoA-I mimetic peptide ameliorating TRPA1-mediated nocifensive behaviour in a model of neurogenic inflammation
por: Oehler, Beatrice, et al.
Publicado: (2020)

LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea
por: Flores, Rhonda, et al.
Publicado: (2019)

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
por: Walldius, Göran, et al.
Publicado: (2021)

Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease
por: Sorokin, Alexander V., et al.
Publicado: (2023)

Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity
por: Kelesidis, Theodoros, et al.
Publicado: (2012)

Autophagy Alteration in ApoA-I Related Systemic Amyloidosis
por: Del Giudice, Rita, et al.
Publicado: (2022)

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
por: Tayyeb, Jehad Z., et al.
Publicado: (2022)

Clinical ApoA‐IV amyloid is associated with fibrillogenic signal sequence
por: Canetti, Diana, et al.
Publicado: (2021)

Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
por: Bencharif, Karima, et al.
Publicado: (2010)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy
por: Gong, Miaomiao, et al.
Publicado: (2019)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

ApoA-I-Mediated Lipoprotein Remodeling Monitored with a Fluorescent Phospholipid
por: Neufeld, Edward B., et al.
Publicado: (2019)

ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity()
por: Lu, Min, et al.
Publicado: (2011)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

Apolipoprotein A-I Mimetic Peptides Prevent Atherosclerosis Development and Reduce Plaque Inflammation in a Murine Model of Diabetes
por: Morgantini, Cecilia, et al.
Publicado: (2010)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction
por: Chen, Yan, et al.
Publicado: (2023)

Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice
por: Sanoudou, D, et al.
Publicado: (2009)

Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome
por: Ng, Theodore W. K., et al.
Publicado: (2009)

Association of serum apoA-I with in-stent restenosis in coronary heart disease
por: Wang, Xin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r9aqm64mhn3iqsq9pn2g47q5pp